Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy (PVWMH)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Hypertensive Arteriopathy; Cerebral Amyloid Angiopathy

Treatments: Other: None, pure observational study

Study type: Observational

Funder types: Other

Identifiers

NCT05486897

LOCAL/2022/DR-04

Details and patient eligibility

About

White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). WMH tend to show a peri-basal ganglia pattern in HA, whereas a multiple subcortical spots pattern can be observed in CAA. Periventricular WMH (PVWMH) have been reported to be posterior predominant using a semiautomated segmentation method and logarithmic transformation, not used in daily clinical practice. In these studies including CAA patients, patients initially presented with haemorrhage-related symptoms. In another study analysing PVWMH and cerebral amyloid evidence in patients with mild cognitive impairment, frontal PVWMH burden was associated with high uptake on florbetapir-PET whereas parietal and occipital PVWMH burden was associated with low CSF-amyloid-beta.

The aim of this study is the descriptive comparative analysis of the distribution of PVWMH between CAA and HA patients with radiological tools available in daily practice.

Enrollment: 315 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022.

Exclusion criteria

CAA and HA patients, treated at the CHU of Nîmes between January 2015 and March 2022, not objecting to the use of their health data

Trial design

315 participants in 2 patient groups

cerebral amyloid angiopathy

Description:

Patient with cerebral amyloid angiopathy

Treatment:

Other: None, pure observational study

Hypertensive arteriopathy

Description:

Patients with hypertensive arteriopathy

Treatment:

Other: None, pure observational study